北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 聯席公司秘書辭任及 變更授權代表及法律程序文件代理人 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 CANbridge Pharmaceuticals Inc. 聯席公司秘書、授權代表及法律程序文件代理人辭任 北海康成製藥有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司之聯席公司秘書之一 黃偉超先生（「黃先生」）已提出辭任本公司聯席公司秘書（「聯席公司秘書」）職務。黃先生亦不再擔任香 港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第3.05條項下的本公司授權代表（「授權 代表」）之一及根據香港法例第622章公司條例第16部在香港代表本公司接收法律程序文件或通知之授 權代表（「法律程序文件代理人」），上述辭任均自2026年3月30日起生效。 黃先生已確認，彼與董事會並無任何意見分歧，亦無有關其辭任之其他事宜須提請聯交所及本公司 股東垂 ...

Strategic Partnerships and Collaborations - The company reported a strategic partnership with Baiyang Pharmaceuticals, receiving a strategic cooperation fee of RMB 50 million and raising approximately HKD 100 million from the subscription of 74,971,468 shares[4] - The strategic partnership with Baiyang Pharmaceutical includes a contract sales organization for marketing services and a share acquisition of 74,971,468 shares, representing 14.99% of the expanded issued share capital, for approximately HKD 100 million[56] - The company aims to expand its commercialization efforts in Greater China, leveraging the partnership with Baiyang Pharmaceutical to enhance its business significantly[57] Product Development and Approvals - The company launched Mai Ruibei® in January 2024, identifying 900 ALGS patients by December 31, 2025, and covering 260 million people in 39 cities with commercial insurance plans[7] - The company received approval for Mai Ruibei® to expand its indication for treating cholestatic pruritus in ALGS patients in May 2024[7] - Go Ruining® was approved for market launch in China in May 2025 and was included in the first version of the commercial insurance innovative drug catalog in December 2025[7] - The company has a comprehensive product line consisting of 7 drug assets, including 3 marketed products and 1 late-stage clinical candidate[48] - MaiRuiBei® has been approved for ALGS in mainland China, Hong Kong, and Taiwan, becoming the first and only product approved for treating ALGS cholestatic pruritus in these regions[63] Financial Performance - Revenue decreased from RMB 85.1 million for the year ending December 31, 2024, to RMB 50.0 million for the year ending December 31, 2025, a decline of RMB 35.1 million or 41.2%[11] - Other income and gains increased from a loss of RMB 5.5 million to a profit of RMB 109.7 million, primarily due to a gain of RMB 101.0 million from the termination of a lease in the U.S.[11] - Profit increased by RMB 457.4 million, turning from a loss of RMB 442.6 million to a profit of RMB 14.8 million, driven by increased other income and reduced expenses[12] - Total revenue for 2025 was RMB 49,983 thousand, a decrease of 41.2% from RMB 85,103 thousand in 2024[29] - The company reported a profit of RMB 14,818,000 for 2025, a significant recovery from a loss of RMB 442,619,000 in 2024[44] Cost Management and Expenses - R&D expenses decreased by RMB 206.7 million or 82.1%, from RMB 251.8 million to RMB 45.1 million, mainly due to the approval of a new drug application for Gorineng®[11] - Administrative expenses reduced by RMB 31.4 million or 46.0%, from RMB 68.2 million to RMB 36.8 million, attributed to cost control efforts[11] - Sales and distribution expenses decreased by RMB 27.5 million or 36.7%, from RMB 74.9 million to RMB 47.4 million, due to the cessation of sales activities for He Lian An®[12] - The implementation of cost control measures and reduction of expenses is crucial for the company's financial health[25] - The company has successfully implemented plans to control costs and reduce expenditures, which are essential for ongoing operations[25] Market Access and Commercialization - The company is actively working on market access for its three products in mainland China, Taiwan, and Hong Kong[5] - The group aims to improve cash flow and profitability through its commercialized products, including HaiRuiSi® and MaiRuiBei®, and accelerate the commercialization of GeRuiNing®, which received approval for treating Gaucher disease[21] - The company plans to continue strengthening its commercialization team to support multiple rare disease products[62] Research and Development - The company is focusing on gene therapy, having obtained a license for the dual-vector technology "StitchR" for treating Duchenne Muscular Dystrophy (DMD) as of December 31, 2025[8] - The company has generated proof-of-concept data for its DMD preclinical research and plans to continue data generation in large animal models[8] - The company is investing in next-generation gene therapy technologies, with a focus on RNA assembly techniques for treating muscular dystrophy[51] Financial Health and Liabilities - The group has a net current liability of approximately RMB 345,173,000 and a net liability of RMB 341,755,000 as of December 31, 2025, raising significant doubts about its ability to continue as a going concern[20] - The company is actively negotiating with banks to renew and extend existing loans due after December 31, 2025, although no binding agreements have been established yet[21] - The group reported net current liabilities of RMB 345.173 million and total liabilities of RMB 341.755 million as of December 31, 2025, indicating significant uncertainty regarding the group's ability to continue as a going concern[113] Employee and Operational Changes - The management team has streamlined to 41 full-time employees, emphasizing expertise in rare disease commercialization[48] - The total employee cost for the group was approximately RMB 50.4 million for the year ending December 31, 2025, down from RMB 97.4 million in 2024[108] - The group had 41 employees as of December 31, 2025, a decrease from 67 employees in 2024[107] Regulatory Compliance and Reporting - The independent auditor confirmed that the financial information in the performance announcement is consistent with the consolidated financial statements for the year ending December 31, 2025[111] - The audit committee reviewed the audited annual results and found them to comply with relevant accounting standards and regulations[114] - The company has adopted a code of conduct for securities trading by directors, confirming compliance through December 31, 2025[105]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容所產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （股份代號：1228） 董事會會議召開日期 北海康成製藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於2026年3月30日（星期一） 舉行董事會會議，藉以（其中包括）考慮並批准本公司及其附屬公司截至2025年12月31日止年度業績 及其發佈。 承董事會命 北海康成製藥有限公司 董事長 薜群博士 香港，2026年3月18日 於本公告日期，董事會包括執行董事薛群博士；非執行董事趙瑋女士及王廷偉先生；以及獨立非執 行董事Richard James Gregory博士、James Arthur Geraghty先生、陳炳鈞先生及胡瀾博士。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 茲提述該公告。除另有界定外，本公告所用詞彙應與該公告所界定者具有相同涵義。 根據上市規則第14A.60(1)條進行的持續關連交易 於完成認購事項後及於本公告日期，認購人已成為本公司主要股東，並因此成為本公司的關連 人士。鑒於WuXi Biologics授權方為認購人共同控制下的聯屬公司，並因此為認購人的聯繫人， WuXi Biologics授權方為本公司的關連人士。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 根據上市規則第14A.60(1)條進行的持續關連交易 於認購事項完成前，北海康成珍愛藥業已與WuXi Biologics授權方訂立多項持續交易，有關交易 於認購事項完成後將繼續。因此，根據上市規則第14A章，獨家許可協議及其項下擬進行的交易 構成本公司的持續關連交易。 上市規則涵義 根據上市規則第14 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接於美國境內或有關刊發或派發屬違法的任何其他司法權區刊 發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告並不構成或組成於美國境內或有關發售屬違法的任何其他司法權區出售證券的任何要約或 招攬購買或認購證券的一部分。本公告所述本公司股份並無亦不會根據1933年美國證券法（經修訂） （「美國證券法」）登記，且不得於美國境內提呈發售或出售，惟根據美國證券法登記規定進行登記者 或獲豁免遵守該等登記規定者除外。本公司無意根據美國證券法登記本公告內所指之任何證券，或 在美國境內進行證券公開發售。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 完成根據一般授權認購新股份 完成根據一般授權認購新股份 1 下表載列本公司於交割時的股權架構變動： | | 緊 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01228 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1 ...

Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant increase in stock price, rising over 6% and reaching a trading price of 2.79 HKD, with a transaction volume of 1.72 million HKD [1] Group 1: Share Placement Announcement - Beihai Kangcheng announced a placement of 84.036 million shares to a subsidiary of WuXi Biologics, representing approximately 14.12% of the enlarged share capital [1] - The net proceeds from the share placement are approximately 199 million HKD, with 12% allocated for operational funds and regulatory maintenance of commercialized products, 28% for research and development expenses of existing product lines, and 60% for settling trade payables of the group [1] - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]

Core Viewpoint - Beihai Kangcheng-B (01228.HK) experienced a significant increase in stock price, rising over 6% at one point and closing with a gain of 5.68% at HKD 2.79, with a trading volume of HKD 1.72 million [1] Summary by Category - **Stock Performance** - The stock price of Beihai Kangcheng-B rose by 5.68% to HKD 2.79 [1] - The stock saw a peak increase of over 6% during the trading session [1] - The total trading volume reached HKD 1.72 million [1]

Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant increase in stock price, rising over 6% in the afternoon trading session, with a current price of 2.79 HKD and a trading volume of 1.72 million HKD [1] Group 1: Share Placement Announcement - Beihai Kangcheng announced a placement of 84.03 million shares to a subsidiary of WuXi Biologics, representing approximately 14.12% of the enlarged share capital [1] - The net proceeds from the share placement are approximately 199 million HKD, with 12% allocated for operational funds and regulatory maintenance of commercialized products, 28% for research and development expenses of existing product lines, and 60% for settling trade payables of the group [1] - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) experienced a significant stock price increase of over 6%, reaching 2.79 HKD with a trading volume of 1.72 million HKD [1] - Beihai Kangcheng announced a placement of 84.03 million shares to a subsidiary of WuXi Biologics, representing approximately 14.12% of the enlarged share capital [1] - The net proceeds from the placement are approximately 199 million HKD, with 12% allocated for operational funds and regulatory maintenance of commercialized products, 28% for R&D expenses of existing product lines, and 60% for settling trade payables [1] Group 2 - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]